Sichenzia Ross Friedman Ference LLP Advises Tonix Pharmaceuticals on $7.8 Million Public Offering
NEW YORK, July 16, 2014 (GLOBE NEWSWIRE) –New York based securities law firm, Sichenzia Ross Friedman Ference LLP, acted as counsel to Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage pharmaceutical company focused on researching common disorders of the central nervous system, on a recently completed $7.8 million registered direct public offering pursuant to Tonix’s shelf registration statement. The offering consisted of 657,000 shares of common stock sold at $11.90 per share. Roth Capital Partners acted as the sole placement agent in this offering. The Sichenzia Ross Friedman Ference LLP team consisted of partners Marc J. Ross and James M. Turner and associate Sharon Carroll.
- Founding Partner Gregory Sichenzia Quoted in Bankrate Article Discussing Prominent IPOs to Keep an Eye On - September 15, 2020
- Sichenzia Ross Ference LLP Represents Vuzix in $15.5 Million Registered Direct Offering - September 10, 2020
- Sichenzia Ross Ference LLP Represents Avinger Inc. in Close of $5.2 Million Underwritten Public Offering of Common Stock - August 26, 2020